Stephan B.
- Country
- Germany
- Department
- Pneumologische Ambulanz
Research Overview
- Efficacy, Safety, and Immunogenicity Comparison of GME751 Versus EU-Authorized Pembrolizumab in Treatment-Naïve Metastatic Non-Small-Cell Lung Cancer Patients
- Phase 3 Study of Pumitamig Versus Pembrolizumab in Previously Untreated Advanced Non-Small Cell Lung Cancer with PD-L1 ≥50%
- Long-term Safety and Tolerability Evaluation of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Data & Insights
Has run more than one trial at 226 of 690 partner sites.
Specializations
Pulmonary Disease Management
The investigator specializes in treating chronic obstructive pulmonary disease (COPD), focusing on innovative therapeutic approaches for moderate to severe cases. Their research encompasses long-term management strategies and evaluation of combination therapies for improving cardiopulmonary outcomes.
- Triple therapy combinations
- COPD exacerbation management
- Bronchodilator treatments
Fibrotic Lung Conditions
Expertise extends to treating various forms of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The investigator explores novel inhaled therapies and long-term treatment approaches for fibrotic lung diseases.
- Innovative inhaled therapeutics
- Lung function preservation
- Progressive fibrosis management
Advanced Lung Cancer Treatment
The investigator focuses on treating non-small cell lung cancer (NSCLC), particularly in advanced stages. Their work involves evaluating combination therapies and investigating new treatment approaches for patients without actionable genomic alterations.
- First-line treatment strategies
- Combination immunotherapy
- Biomarker-driven treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.